IDEAYA Biosciences Soars 10.07% on Clinical Trial Expansion

On April 21, 2025, IDEAYA Biosciences experienced a significant rise of 10.07% in pre-market trading, reflecting a strong start to the day's trading session.

IDEAYA Biosciences recently announced the initiation of a Phase 1/2 expansion in a clinical trial evaluating IDE397, a potential first-in-class small molecule inhibitor, in combination with Gilead's Trodelvy®, for MTAP-deletion urothelial cancer. This expansion is based on preliminary safety and clinical efficacy data, indicating promising results from the ongoing study.

The company also reported a successful FDA Type D meeting on the Phase 3 registrational trial design for Darovasertib as a neoadjuvant therapy for primary uveal melanoma. This meeting is a crucial step in advancing the development of Darovasertib, which could potentially offer a new treatment option for patients with this rare form of cancer.

IDEAYA Biosciences has also announced its participation in upcoming April 2025 investor relations events, providing an opportunity for the company to engage with investors and discuss its strategic initiatives and financial performance.